How to treat genetic diseases using recent strategies

Numerous viewpoints and paradigms in medicine have been altered by genetics and molecular genetic approaches. Numerous diseases have been treated or made less severe using genetic techniques. The use of genetic materials and associated methods to treat various human ailments is known as gene therapy. A review of current medical and therapeutic trends reveals that gene therapy has drawn significant interest because of its great potential to treat a variety of ailments. Gene therapy can make use of a variety of genetic resources, including DNA, single- and double-stranded RNA, siRNA, and shRNA. ZNF, TALEN, and CRISPR-Cas9 are the primary gene editing methods utilized for in vitro and in vivo gene alteration. The latter has raised expectations for a more accurate and effective sequence.

When choosing an illness to be treated using gene therapy, several characteristics are taken into account, including the high cost of current medicines, the lack of a successful treatment, and crippling disorders that afflict more than 1% of the population. The first successful gene transfer into the nucleus of a human cell was accomplished by the National Institutes of Health. Numerous clinical trials were started and carried out on the patients after the first successful gene modification for the well-known patient Ashanti De Silva. The rejection of gene therapy was caused by an increase in failures and even participant deaths. Many of the investigations were progressively redirected back to this sort of treatment as a result of multiple fruitful experiments and clinical studies. There are three primary types of gene therapy.

Yoshimizumi and his associates' 1987 work is where the concept of using a clustered DNA sequence was first proposed. Francisco Mojica was the first to describe the bacterial CRISPR locus. These remnants of bacteriophage sequences that formerly infected the bacterium teach us about the prokaryotes' ingenious defense systems against incoming bacteriophages. Therefore, these clustered sequences should be regarded as the bacterium's adaptive immune system because bacteria retain them and use them to identify and destroy bacteriophage DNA during infection. 90% of archaea and roughly 50% of bacterial genomes contain CRISPR sequences. The enzyme known as Cas9 is responsible for recognizing CRISPR fragments and cleaving their complementary DNA at predetermined cleavage sites. In situ gene editing of the uses CRISPR-Cas9.

In what is regarded as the first CRISPR clinical study, the autologous genes from T cells were modified using CRISPR-Cas9 to produce a cancer immunotherapy. After that, CRISPR procedures were used in numerous trials. To transport genetic materials from the lab to the body, target tissue, and cells, an appropriate carrier must be present. The kind of target tissue, the amount of the genetic cargo, and the immediate or temporary impact on the target cells are some of the factors that define the best vector for delivering the genetic materials. The herpes virus would be the ideal potential vector, for instance, if the target cell was located in the peripheral nervous system. There are various kinds of vectors, which can be broadly categorized into viral and non-viral vectors.

The 2000s saw the development of oncolytic viral therapy for the treatment of cancer. This therapy was created as a result of the finding that tumor growth was inhibited by oncolytic viral infection. A person with chronic myelogenic leukemia contracted influenza in 1940. The doctors saw a considerable decrease in the patient in question's high white blood cell count during the period of influenza infection. This finding suggested that influenza viruses may have oncolytic properties. More instances of these improvements brought on by exposure to other viruses were seen between 1950 and 1980, including the improvement of acute lymphoblastic leukemia in smallpox patients and a decrease in the number of white blood cells in a leukemia patient who also had measles.